Consensus

DOI: 10.4244/EIJ-JAA-202501

Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society

Jean-Claude Deharo1,2; Julien Dreyfus3; Maria-Grazia Bongiorni4; Haran Burri5; Pascal Defaye6; Michael Glikson7; Nigel Lever8; Antonio Mangieri9; Blandine Mondésert10; Jens Cosedis Nielsen11,12; Maully Shah13; Christoph Thomas Starck14; Archana Rao15; Christophe Leclercq16; Fabien Praz17

Abstract

Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI. Graphical abstract.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 22
Nov 14, 2025
Volume 21 Number 22
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00453 Jul 6, 2026
AnchorMan versus Watchman 2.5: a randomised comparison in left atrial appendage closure
Garot P and Nielsen-Kudsk J
free

Editorial

10.4244/EIJ-E-26-00011 Jul 6, 2026
Comparing transcatheter aortic valves: time to look beyond simplistic categorisations
Blackman D and Maznyczka A
free

Original Research

10.4244/EIJ-D-26-00158 Jul 6, 2026
Prosthesis-patient mismatch with intra-annular self-expanding valves: an analysis of the PORTICO IDE trial
Fontana G et al

Research Correspondence

10.4244/EIJ-D-26-00315 Jul 6, 2026
Validation of the VARC-HBR consensus for defining high bleeding risk in TAVI
Singh M et al

Research Correspondence

10.4244/EIJ-D-26-00271 Jul 6, 2026
Outcomes of percutaneous mechanical aspiration in left-sided infective endocarditis
Lugo-Fagundo NS et al

Flashlight

10.4244/EIJ-D-26-00128 Jul 6, 2026
Concomitant transfemoral aortic and mitral valve replacement
Lianos I et al
Trending articles
334.7

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
45.75

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
32.2

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
29.2

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
29.2

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved